GENE ONLINE|News &
Opinion
Blog

2020-04-20| In-DepthR&D

Cancer Drug Resistance: Implications in Cancer Therapy

by Tulip Chakraborty
Share To

By T. Chakraborty, Ph.D.

Introduction

Cancer is the second most common cause of death in the human population right behind heart diseases. Approximately 10 million people die of cancer every year which in turn is a huge socioeconomic burden to society. The United States alone had 1.7 million people diagnosed with cancer with approximately 600,000 deaths in the year 2018 [1]. Even with the improvement of drug target identification and precision medicine, the field of cancer therapy continues to face the hurdle of drug resistance. Cancer cells often acquire the ability to survive and grow in the host through the process of drug resistance, which ultimately leads to the ineffectiveness of cancer therapies.

 

What is Cancer Drug Resistance?

It is well documented that overdose of antibiotics can cause antibiotic resistance in bacteria by the natural selection of resistant strains. Similarly, rapidly dividing cells can develop mutations and resistance towards the drugs which result in the selection of cancer cells resistant to therapies. Before the advent of immunotherapies, chemotherapy or molecularly targeted therapies via inhibitors were the most preferred cancer treatments. However, cancer cells have developed ways to evade these interventions and develop resistance against drugs. Some of these resistances are intrinsic, meaning, the individual has pre-existing factors that make the cancer cells resistant to the drug while some are acquired as the treatment progresses [2].

 

Drug Resistance Mechanisms in Cancer

Drug Efflux

Of the various known mechanisms, drug efflux is one of the major ones through which cancer cells evade therapies. Many transmembrane efflux pumps have been linked to the development of resistance towards chemotherapy and targeted molecular therapies. The most notable of these is the ATP-binding cassette (ABC) class of transporters. With around 49 members in this family, this diverse class of proteins has been shown to pump out the drugs from cancer cells, making them resistant. Of the 49 members, the predominantly studied proteins are multi-drug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP). Though MDR1 inhibitors like zosuquidar and tariquidar initially showed promise in pre-clinical studies, the trials failed probably owing to the redundancy and diversity of these ABC transporters [3, 4, 5].

SLC Proteins

Certain drugs can penetrate the cells through passive diffusion or absorption of solute carrier proteins (SLC). Cancers have been found to reduce the expression of these SLC proteins or reduce their binding capacity, thereby decreasing intake [6]. They can also evade targeted therapies by changing their expression levels, a phenomenon they achieve by mutating drug targets. For example, androgen receptors are upregulated in prostate cancer patients who are treated with androgen receptor antagonists, bicalutamide. Increased target expression, in this case, reduces the drug efficacy leading to drug resistance [7].

Drug Metabolism

Modifications in drug metabolism is another established mechanism. Higher activity of cytochrome P450 enzyme has been observed to induce resistance against breast cancer drug docetaxel. Reducing the enzyme activity increases drug efficacy, demonstrating the importance of drug metabolism in cancer drug resistance development [6, 8].

DNA damaging agents

Chemotherapeutic agents act against the cancers by damaging their DNA. The usual response to that is either cell death or DNA repair. Cancer cells have been shown to develop chemotherapeutic resistance by upregulating DNA repair mechanisms and inhibiting cell death by upregulating anti-apoptotic pathways. Molecular therapies against key proteins of the DNA repair machinery is a proven approach to deal with such a challenge. A prime example is a poly (ADP–ribose) polymerase 1 (PARP1) inhibitor that is used to combat drug resistance in breast cancer [9].

 

Cancer Heterogeneity and Tumor Microenvironment

The tumor microenvironment, and heterogeneity, that refers to the cell to cell variation, also play a critical role in the development of drug resistance [10]. Resistant cells get selected during cancer growth and propagation through genetic alterations and the genetic diversity of a malignant tumor. Additionally, the tumor microenvironment that comprises of immune cells, vasculature, etc. mediates the development of drug resistance by inhibiting tumor clearance and drug absorption. The influence of this microenvironment has been further underscored by the success of immunotherapies and immune checkpoint blockade proteins like TIGIT, and others [11].

 

Fighting against Cancer Drug Resistance

Drug resistance can be mitigated by limiting the heterogeneity and genetic diversity of the cancerous tissue, something that could be achieved through early detection. The development of methods to detect circulating DNA from tumor cells has largely aided this cause [12]. AVENIO family of next-generation sequencing assays by Roche is one such method that can be used for the rapid identification of circulating DNA in early cancer patients [13].

Other methods include local therapy targeted to cancer cells, immunotherapy using the immune-checkpoint proteins as well as monitoring the response to drugs from time to time to understand drug efficacy. Orthogonal therapies targeting multiple pathways is also a strategy that holds much potential. Using high throughput methods like next-gen sequencing on patient-derived cancer cells can provide valuable inputs on the intrinsic and extrinsic drug resistance at the genetic level.

 

Nanomedicine

Nanomedicine has been promoted as the future of cancer therapy as it has various properties to circumvent drug resistance development. Many nanoparticles mediated delivery is dependent on passive delivery and has been shown to have enhanced retention than traditional therapies. The addition of polyethylene glycol to nanoparticles has been shown to increase circulation time leading to higher drug absorption [14]. Most of the nanoparticles are still under investigation. Of the current FDA approved therapies, Johnson and Johnson’s Doxil (doxorubicin HCl) authorized for ovarian cancer, breast cancer, and multiple myeloma is of particular interest [15].

 

Future Directions

Understanding the molecular basis of cancer drug resistance will open up new avenues in cancer treatments. Combining various strategies, like understanding the physical nature of the tumor, the microenvironment, genetic variations among others are gaining traction. Besides, studying the potential targets, early detection and targeted therapy will also help in reducing drug resistance. Furthermore, in the era of precision medicine, patient-derived organoids [16] could shed new light on the patient-specific drug resistance, the understanding of which will result in improved therapies.

Editor: Rajaneesh K. Gopinath, Ph.D.

Related Article: The Evolution of Lung Cancer Therapies at a Glance

References
  1. https://www.cancer.gov/about-cancer/understanding/statistics
  2. https://www.nature.com/articles/nrc3599
  3. https://www.ncbi.nlm.nih.gov/pubmed/15986399
  4. https://www.ncbi.nlm.nih.gov/pubmed/19241078
  5. https://www.ncbi.nlm.nih.gov/pubmed/15324696
  6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651054/
  7. https://www.ncbi.nlm.nih.gov/pubmed/9076469
  8. https://www.ncbi.nlm.nih.gov/pubmed/23523389
  9. https://www.nature.com/articles/nature03445
  10. https://www.nature.com/articles/s41586-019-1730-1#Sec2
  11. https://science.sciencemag.org/content/359/6382/1350
  12. https://www.nature.com/articles/nrc.2017.7
  13. https://sequencing.roche.com/en-us/products-solutions/by-category/assays.html?_bk=ctdna&_bt=358169879448&_bm=e&_bn=g&bg=46669829262&gclid=Cj0KCQjwyur0BRDcARIsAEt86IAjorjyj4USam4VLDogrJT_XYebLJkFrDkxHnoxnxCgsuEBWQaAzZ4aAnpREALw_wcB
  14. https://www.sciencedirect.com/science/article/pii/S0169409X13002329
  15. https://www.cancer.gov/nano/cancer-nanotechnology/current-treatments
  16. https://www.ncbi.nlm.nih.gov/pubmed/30213835

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
Zenas Picks Up $118 Million To Advance Phase 3 For Autoimmune Candidate
2022-11-10
R&D
Combining STING Agonists and pHLIPs to Enhance Cancer Treatments
2022-11-09
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!